Universität zu Köln

2022

Huober, J., Janni, W., Untch, M., Blohmer, J-U., Zahm, D-M., Hanusch, C., Jackisch, C., Heinrich, G., Schneeweiss, A., Denkert, C., Link, T., Rhiem, K. E., Furlanetto, J., Solbach, C., Klare, P., Nekljudova, V., Filmann, N. and Loibl, S. (2022). Long-term survival of a randomised, open-label, phase II study comparing the efficacy and safety of cabazitaxel versus weekly paclitaxel given as neoadjuvant treatment in patients with operable triple-negative or luminal B/HER2-negative breast cancer (GENEVIEVE). Ann. Oncol., 33 (7). S. S615 - 1. AMSTERDAM: ELSEVIER. ISSN 1569-8041

Laakmann, E., Riecke, K., Neunhoeffer, T., Park-Simon, T-W., Weide, R., Polasik, A., Schmidt, M., Puppe, J., Fasching, P. A., Hesse, T., Decker, T., Denkert, C., Fehm, T. N., Nekljudova, V., Rey, J., Loibl, S., Mueller, V. and Witzel, I. (2022). Long-term survival of HER2-positive breast cancer patients with brain metastases: Subanalysis of the BMBC registry. Ann. Oncol., 33 (7). S. S660 - 1. AMSTERDAM: ELSEVIER. ISSN 1569-8041

Loibl, S., Reinisch, M., Denkert, C., Fasching, P. A., Seiler, S., Link, T., Hanusch, C., Bjelic-Radisic, V., Schneeweiss, A., Huober, J., Jackisch, C., Rhiem, K. E., Untch, M., Solbach, C., Blohmer, J-U., Buechele, T., Nekljudova, V. and Loi, S. (2022). A randomized, open-label, phase II trial comparing neoadjuvant trastuzumab, pertuzumab and endocrine therapy +/- the PI3K inhibitor inavolisib in patients (pts) with HER2+/HR+, PIK3CA mutant early breast cancer (BC)-GeparPiPPa. Ann. Oncol., 33 (7). S. S627 - 1. AMSTERDAM: ELSEVIER. ISSN 1569-8041

Loibl, S., Schneeweiss, A., Huober, J., Braun, M., Rey, J., Blohmer, J. U., Furlanetto, J., Zahm, D. M., Hanusch, C., Thomalla, J., Jackisch, C., Staib, P., Link, T., Rhiem, K., Solbach, C., Fasching, P. A., Nekljudova, V., Denkert, C. and Untch, M. (2022). Neoadjuvant durvalumab improves survival in early triple-negative breast cancer independent of pathological complete response. Ann. Oncol., 33 (11). S. 1149 - 1159. AMSTERDAM: ELSEVIER. ISSN 1569-8041

Reinisch, M., Blohmer, J-U., Link, T., Just, M., Untch, M., Stoetzer, O., Fasching, P. A., Schneeweiss, A., Wimberger, P., Seiler, S., Huober, J., Thill, M., Jackisch, C., Rhiem, K., Solbach, C., Hanusch, C., Denkert, C., Engels, K., Nekljudova, V. and Loibl, S. (2022). Patient quality of life (QoL) from the GeparX trial on the addition of denosumab (Dmab) added to two different nab-paclitaxel (nP) regimens as neoadjuvant chemotherapy (NACT) in primary breast cancer (BC). Ann. Oncol., 33. S. S166 - 2. AMSTERDAM: ELSEVIER. ISSN 1569-8041

Riecke, K., Laakmann, E., Neunhoffer, T., Park-Simon, T-W., Weide, R., Schmidt, M., Polasik, A., Puppe, J., Mundhenke, C., Luebbe, K., Hesse, T., Thill, M., Zahm, D-M., Denkert, C., Fehm, T., Nekljudova, V., Rey, J., Loibl, S., Mueller, V. and Witzel, I. (2022). Long-term survival of breast cancer patients with brain metastases: Subanalysis of the BMBC registry. Ann. Oncol., 33. S. S202 - 2. AMSTERDAM: ELSEVIER. ISSN 1569-8041

2021

Laakmann, E., Witzel, I., Neunhoeffer, T., Park-Simon, T-W., Weide, R., Riecke, K., Polasik, A., Schmidt, M., Puppe, J., Mundhenke, C., Luebbe, K., Hesse, T., Thill, M., Zahm, D-M., Denkert, C., Fehm, T., Nekljudova, V., Rey, J., Loibl, S. and Mueller, V. (2021). Characteristics of patients with brain metastases from HER2-positive breast cancer. Ann. Oncol., 32. S. S63 - 2. AMSTERDAM: ELSEVIER. ISSN 1569-8041

Llop-Guevara, A., Loibl, S., Villacampa, G., Vladimirova, V., Schneeweiss, A., Karn, T., Zahm, D. -m., Herencia-Ropero, A., Jank, P., van Mackelenbergh, M., Fasching, P. A., Marme, F., Stickeler, E., Schem, C., Dienstmann, R., Florian, S., Nekljudova, V., Balmana, J., Hahnen, E., Denkert, C. and Serra, V. (2021). Association of RAD51 with homologous recombination deficiency (HRD) and clinical outcomes in untreated triple-negative breast cancer (TNBC): analysis of the GeparSixto randomized clinical trial. Ann. Oncol., 32 (12). S. 1590 - 1597. AMSTERDAM: ELSEVIER. ISSN 1569-8041

2020

Link, T., Blohmer, J-U., Just, M., Untch, M., Stoetzer, O., Fasching, P. A., Schneeweiss, A., Wimberger, P., Seiler, S., Huober, J., Schmitt, W. D., Jackisch, C., Rhiem, K. E., Hanusch, C., Denkert, C., Sinn, B. V., Engels, K., Nekljudova, V. and Loibl, S. (2020). GeparX: Denosumab (Dmab) as add-on to different regimen of nab-paclitaxel (nP)-anthracycline based neoadjuvant chemotherapy (NACT) in early breast cancer (BC): Subgroup analyses by RANK expression and HR status. Ann. Oncol., 31. S. S308 - 2. AMSTERDAM: ELSEVIER. ISSN 1569-8041

Schneeweiss, A., Moebus, V., Tesch, H., Klare, P., Denkert, C., Kast, K., Hanusch, C., Link, T., Untch, M., Jackisch, C., Blohmer, J-U., Fasching, P. A., Solbach, C., Huober, J., Rhiem, K. E., Nekljudova, V., Luebbe, K. and Loibl, S. (2020). Survival analysis of the randomized phase III GeparOcto trial comparing neoadjuvant chemotherapy (NACT) of iddEPC versus weekly paclitaxel, liposomal doxorubicin (plus carboplatin in triplenegative breast cancer, TNBC) (PM(Cb)) for patients (pts) with highrisk early breast cancer (BC). Ann. Oncol., 31. S. S303 - 2. AMSTERDAM: ELSEVIER. ISSN 1569-8041

2018

Loibl, S., Weber, K. E., Timms, K. M., Elkin, E. P., Hahnen, E., Fasching, P. A., Lederer, B., Denkert, C., Schneeweiss, A., Braun, S., Salat, C. T., Rezai, M., Blohmer, J. U., Zahm, D. M., Jackisch, C., Gerber, B., Klare, P., Kuemmel, S., Schem, C., Paepke, S., Schmutzler, R., Rhiem, K., Penn, S., Reid, J., Nekljudova, V., Hartman, A-R, von Minckwitz, G. and Untch, M. (2018). Survival analysis of carboplatin added to an anthracycline/taxane-based neoadjuvant chemotherapy and HRD score as predictor of response-final results from GeparSixto. Ann. Oncol., 29 (12). S. 2341 - 2348. OXFORD: OXFORD UNIV PRESS. ISSN 1569-8041

Pohl, E., Schneeweiss, A., Hauke, J., Moebus, V., Furlanetto, J., Denkert, C., Fasching, P. A., Hanusch, C., Tesch, H., Weber-Lassalle, N., Mueller, V., Rhiem, K., Untch, M., Luebbe, K., Lederer, B., Jackisch, C., Nekljudova, V., Schmutzler, R. K., Hahnen, E. and Loibl, S. (2018). Germline mutation status and therapy response in patients with triple-negative breast cancer (TNBC): Results of the GeparOcto study. Ann. Oncol., 29. OXFORD: OXFORD UNIV PRESS. ISSN 1569-8041

Untch, M., Jackisch, C., Schneeweiss, A., Schmatloch, S., Aktas, B., Denkert, C., Schem, C., Wiebringhaus, H., Kuemmel, S., Rhiem, K., Warm, M., Fasching, P. A., Just, M., Hanusch, C., Hackmann, J., Blohmer, J-U., Furlanetto, J., Nekljudova, V., von Minckwitz, G. and Loibl, S. (2018). Impact of nab-paclitaxel dose reduction on survival of the randomized phase III GeparSepto trial comparing neoadjuvant chemotherapy of weekly nab-paclitaxel (nP) with solvent-based paclitaxel (P) followed by anthracycline/cyclophosphamide for patients with early breast cancer (BC). Ann. Oncol., 29. S. 60 - 61. OXFORD: OXFORD UNIV PRESS. ISSN 1569-8041

2017

von Minckwitz, G., Timms, K., Untch, M., Elkin, E. P., Hahnen, E., Fasching, P. A., Schneeweiss, A., Salat, C. T., Rezai, M., Blohmer, J-U, Zahm, D-M, Jackisch, C., Gerber, B., Klare, P., Kummel, S., Paepke, S., Schmutzler, R., Chau, S., Reid, J., Hartman, A-R, Nekljudova, V., Weber, K. E. and Loibl, S. (2017). Homologous repair deficiency (HRD) as measure to predict the effect of carboplatin on survival in the neoadjuvant phase II trial GeparSixto in triple-negative early breast cancer. Cancer Res., 77. PHILADELPHIA: AMER ASSOC CANCER RESEARCH. ISSN 1538-7445

2011

Moebus, V., Diel, I. J., Harbeck, N., Elling, D., Jackisch, C., Thomssen, C., Untch, M., Conrad, B., Schneeweiss, A., Kreienberg, R., Huober, J., Mueller, V., Lueck, H-J, Bauerfeind, I., Loibl, S., Nekljudova, V. and von Minckwitz, G. (2011). GAIN Study: A Phase III Trial To Compare ETC vs. EC-TX and Ibandronate vs. Observation in Patients with Node-Positive Primary Breast Cancer 1st Interim Efficacy Analysis. Cancer Res., 71. PHILADELPHIA: AMER ASSOC CANCER RESEARCH. ISSN 1538-7445